Gene expression of inflammatory molecules in circulating lymphocytes from arsenic-exposed human subjects

Environmental Health Perspectives

Volumn 111, Issue 11, 2003, Pages 1429-1438

  Wu, Meei Maan ^a   Chiou, Hung Yi ^b   Ho, I Ching ^a   Chen, Chien Jen ^c   Lee, Te Chang ^a,d  

^a INSTITUTE OF BIOMEDICAL SCIENCES   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^d NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

Arsenic exposure; Atherosclerosis; Gene expression; Inflammation

Indexed keywords

ALPHA CHEMOKINE; ARSENIC; BETA CHEMOKINE; CD14 ANTIGEN; COMPLEMENTARY DNA; CYTOKINE; GROWTH FACTOR; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERSTITIAL COLLAGENASE; LIGAND; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; BLOOD LEVEL; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; DEMOGRAPHY; DNA HYBRIDIZATION; DNA MICROARRAY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION REGULATION; GENE TARGETING; GENETIC ASSOCIATION; GENETIC TOXICOLOGY; GENETIC TRANSCRIPTION; HIGH RISK POPULATION; HUMAN; HUMAN CELL; INFLAMMATORY INFILTRATE; LONG TERM EXPOSURE; LYMPHOCYTE ACTIVATION; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NUCLEOTIDE SEQUENCE; ONCOGENE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN MOTIF; RISK FACTOR; RNA ISOLATION; SMOKING; STATISTICAL SIGNIFICANCE; TAIWAN; UNINDEXED SEQUENCE; UPREGULATION;

EUKARYOTA;

EID: 0041351902     PISSN: 00916765     EISSN: None     Source Type: Journal    
DOI: 10.1289/ehp.6396     Document Type: Article

References (69)

1. Bagla P, Kaiser J. 1996. India's spreading health crisis draws global arsenic experts. Science 274:174-175.
2. Barchowsky A, Dudek EJ, Treadwell MD, Wetterhahn KE. 1996. Arsenic induces oxidant stress and NF-kappa B activation in cultured aortic endothelial cells. Free Radic Biol Med 21:783-790.
3. Barchowsky A, Roussel RR, Klei LR, James PE, Ganju N, Smith KR, et al. 1999. Low levels of arsenic trioxide stimulate proliferative signals in primary vascular cells without activating stress effector pathways. Toxicol Appl Pharmacol 159:65-75.
4. Bates MN, Smith AH, Hopenhayn-Rich C. 1992. Arsenic ingestion and internal cancers: a review. Am J Epidemiol 135:462-476.
5. Bendeck MP. 2002. Matrix metalloproteinases: are they antiatherogenic but proaneurysmal? Circ Res 90:836-837.
6. Bernstam L, Nriagu J. 2000. Molecular aspects of arsenic stress. J Toxicol Environ Health B Crit Rev 3:293-322.
7. Cavigelli M, Li WW, Lin A, Su B, Yoshioka K, Karin M. 1996. The tumor promoter arsenite stimulates AP-1 activity by inhibiting a JNK phosphatase. Embo J 15:6269-6279.
8. Chen CJ, Chiou HY, Chiang MH, Lin LJ, Tai TY. 1996. Dose-response relationship between ischemic heart disease mortality and long-term arsenic exposure. Arterioscler Thromb Vasc Biol 16:504-510.
9. Chen CJ, Hsu LI, Tseng CH. 1999. Emergent epidemics of arseniasis in Asia. In: Arsenic Exposure and Health Effects (Chappell WR, Abernathy CO, Calderon RL, eds). Amsterdam: Elsevier, 113-121.
10. Chen, CJ, Hsueh YM, Lai MS, Shyu MP, Chen SY, Wu MM, et al. 1995. Increased prevalence of hypertension and long-term arsenic exposure. Hypertension 25:53-60.
11. Chen CJ, Wu MM, Lee SS, Wang JD, Cheng SH, Wu HY. 1988. Atherogenicity and carcinogenicity of high-arsenic artesian well water. Multiple risk factors and related malignant neoplasms of blackfoot disease. Arteriosclerosis 8:452-460.
12. Chen H, Liu J, Merrick BA, Waalkes MP. 2001. Genetic events associated with arsenic-induced malignant transformation: applications of cDNA microarray technology. Mol Carcinog 30:79-87.
13. Chen JJ, Wu R, Yang PC, Huang JY, Sher YP, Han MH, et al. 1998. Profiling expression patterns and isolating differentially expressed genes by cDNA microarray system with colorimetry detection. Genomics 51:313-324.
14. Chiou HY, Huang WI, Su CL, Chang SF, Hsu YH, Chen CJ. 1997. Dose-response relationship between prevalence of cerebrovascular disease and ingested inorganic arsenic. Stroke 28:1717-1723.
15. Chouchane S, Snow ET. 2001. In vitro effect of arsenical compounds on glutathione-related enzymes. Chem Res Toxicol 14:517-522.
16. DeKoter RP, Singh H. 2000. Regulation of B lymphocyte and macrophage development by graded expression of PU.1. Science 288:1439-1441.
17. Devitt A, Moffatt OD, Raykundalia C, Capra JD, Simmons DL, Gregory CD. 1998. Human CD14 mediates recognition and phagocytosis of apoptotic cells. Nature 392:505-509.
18. Dong Z. 2002. The molecular mechanisms of arsenic-induced cell transformation and apoptosis. Environ Health Perspect 110(suppl 5):757-759.
19. Elbirt KK, Bonkovsky HL. 1999. Heme oxygenase: recent advances in understanding its regulation and role. Proc Assoc Am Physicians 111:438-447.
20. Engel RR, Hopenhayn-Rich C, Receveur O, Smith AH. 1994. Vascular effects of chronic arsenic exposure: a review. Epidemiol Rev 16:184-209.
21. Engelse MA, Neele JM, van Achterberg TA, van Aken BE, van Schaik RH, Pannekoek H, at al. 1999. Human activin-A is expressed in the atherosclerotic lesion and promotes the contractile phenotype of smooth muscle cells. Circ Res 85:931-939.
22. Everett AD, Stoops T, McNamara CA. 2001. Nuclear targeting is required for hepatoma-derived growth factor-stimulated mitogenesis in vascular smooth muscle cells. J Biol Chem 276:37564-37568.
23. Germolec DR, Spalding J, Boorman GA, Wilmer JL, Yoshida T, Simeonova PP, et al. 1997. Arsenic can mediate skin neoplasia by chronic stimulation of keratinocyte-derived growth factors. Mutat Res 386:209-218.
24. Germolec DR, Spalding J, Yu HS, Chen GS, Simeonova PP, Humble MC, at al. 1998. Arsenic enhancement of skin neoplasia by chronic stimulation of growth factors. Am J Pathol 153:1775-1785.
25. Hampe A, Shamoon BM, Gobet M, Sherr CJ, Galibert F. 1989. Nucleotide sequence and structural organization of the human FMS proto-oncogene. Oncogene Res 4:9-17.
26. Hsueh YM, Wu WL, Huang YL, Chiou HY, Tseng CH, Chen CJ. 1998. Low serum carotene level and increased risk of ischemic heart disease related to long-term arsenic exposure. Atherosclerosis 141:249-257.
27. Huo Y, Weber C, Forlow SB, Sperandio M, Thatte J, Mack M, et al. 2001. The chemokine KC, but not monocyte chemoattractant protein-1, triggers monocyte arrest on early atherosclerotic endothelium. J Clin Invest 108:1307-1314.
28. Kitchin, KT. 2001. Recent advances in arsenic carcinogenesis: modes of action, animal-model systems, and methylated arsenic metabolites. Toxicol Appl Pharmacol 172:249-261.
29. Klouche M, Rose-John S, Schmiedt W, Bhakdi S. 2000. Enzymatically degraded, nonoxidized LDL induces human vascular smooth muscle cell activation, foam cell transformation, and proliferation. Circulation 101:1799-1805.
30. Kokura S, Yoshida N, Yoshikawa T. 2002. Anoxia/reoxygenation-induced leukocyte-endothelial cell interactions. Free Radic Biol Med 33:427-432.
31. Kumar S. 1997. Widescale arsenic poisoning found in South Asia. Lancet 349:1378.
32. Lee TC, Ho IC. 1994. Differential cytotoxic effects of arsenic on human and animal cells. Environ Health Perspect 102(suppl 3):101-105.
33. Li M, Cai JF, Chiu JF. 2002. Arsenic induces oxidative stress and activates stress gene expressions in cultured lung epithelial cells. J Cell Biochem 87:29-38.
34. Libby P. 2002. Inflammation in atherosclerosis. Nature 420:868-874.
35. Libby P, Ridker PM, Maseri A. 2002. Inflammation and atherosclerosis. Circulation 105:1135-1143.
36. Libermann TA, Baltimore D. 1990. Activation of interleukin-6 gene expression through the NF-kappa B transcription factor. Mol Cell Biol 10:2327-2334.
37. Liu Y, Guyton KZ, Gorospe M, Xu Q, Lee JC, Holbrook NJ. 1996. Differential activation of ERK, JNK/SAPK and P38/CSBP/RK map kinase family members during the cellular response to arsenite. Free Radic Biol Med 21:771-781.
38. Lu T, Liu J, LeCluyse EL, Zhou YS, Cheng ML, Waalkes MP. 2001. Application of cDNA microarray to the study of arsenic-induced liver diseases in the population of Guizhou, China. Toxicol Sci 59:185-192.
39. Ludwig S, Hoffmeyer A, Goebeler M, Kilian K, Hafner H, Neufeld B, et al. 1998. The stress inducer arsenite activates mitogen-activated protein kinases extracellular signal-regulated kinases 1 and 2 via a MAPK kinase 6/p38-dependent pathway. J Biol Chem 273:1917-1922.
40. Morrison TB, Weis JJ, Wittwer CT. 1998. Quantification of low-copy transcripts by continuous SYBR Green I monitoring during amplification. Biotechniques 24:954-958, 960, 962.
41. Nakagawa Y, Akao Y, Morikawa H, Hirata I, Katsu K, Naoe T, et al. 2002. Arsenic trioxide-induced apoptosis through oxidative stress in cells of colon cancer cell lines. Life Sci 70:2253-2269.
42. Nathe TJ, Deou J, Walsh B, Bourns B, Clowes AW, Daum G. 2002. Interleukin-1 beta inhibits expression of p21(WAF1/CIP1) and p27(KIP1) and enhances proliferation in response to platelet-derived growth factor-BB in smooth muscle cells. Arterioscler Thromb Vasc Biol 22:1293-1298.
43. Nordstrom K. 2002. Worldwide occurrences of arsenic in ground water. Science 296:2143-2144.
44. Rosenfeld ME. 2002. Leukocyte recruitment into developing atherosclerotic lesions: the complex interaction between multiple molecules keeps getting more complex. Arterioscler Thromb Vasc Biol 22:361-363.
45. Ross R. 1986. The pathogenesis of atherosclerosis - an update. N Engl J Med 314:488-500.
46. Ross R. 1999. Atherosclerosis - an inflammatory disease. N Engl J Med 340:115-126.
47. Roussel RR, Barchowsky A. 2000. Arsenic inhibits NF-kappa B-mediated gene transcription by blocking IkappaB kinase activity and IkappaBalpha phosphorylation and degradation. Arch Biochem Biophys 377:204-212.
48. Schonbeck U, Mach F, Sukhova GK, Murphy C, Bonnefoy JY, Fabunmi RP, et al. 1997. Regulation of matrix metalloproteinase expression in human vascular smooth muscle cells by T lymphocytes: a role for CD40 signaling in plaque rupture? Circ Res 81:448-454.
49. Shin WS, Szuba A, Rockson SG. 2002. The role of chemokines in human cardiovascular pathology: enhanced biological insights. Atherosclerosis 160:91-102.
50. Snow ET. 1992. Metal carcinogenesis: mechanistic implications. Pharmacol Ther 53:31-65.
51. Swart GW. 2002. Activated leukocyte cell adhesion molecule (CD166/ALCAM): developmental and mechanistic aspects of cell clustering and cell migration. Eur J Cell Biol 81:313-321.
52. Theodosiou A, Ashworth A. 2002. Differential effects of stress stimuli on a JNK-inactivating phosphatase. Oncogene 21:2387-2397.
53. Thornton I, Farago M. 1997. The geochemistry of arsenic. London:Chapman & Hall.
54. Tseng WP. 1977. Effects and dose-response relationships of skin cancer and blackfoot disease with arsenic. Environ Health Perspect 19:109-119.
55. Tseng CH, Chong CK, Chen CJ, Lin BJ, Tai TY. 1995. Abnormal peripheral microcirculation in seemingly normal subjects living in blackfoot-disease-hyperendemic villages in Taiwan. Int J Microcirc Clin Exp 15:21-27.
56. Tseng CH, Chong CK, Chen CJ, Tai TY. 1996. Dose-response relationship between peripheral vascular disease and ingested inorganic arsenic among residents in blackfoot disease endemic villages in Taiwan. Atherosclerosis 120:125-133.
57. Tseng CH, chong CK, Chen CJ, Tai TY. 1997. Lipid profile and peripheral vascular disease in arseniasis-hyperendemic villages in Taiwan. Angiology 48:321-335.
58. Tseng CH, Tai TY, Chong CK, Tseng CP, Lai MS, Lin BJ, et al. 2000. Long-term arsenic exposure and incidence of non-insulin-dependent diabetes mellitus: a cohort study in arseniasis-hyperendemic villages in Taiwan. Environ Health Perspect 108:847-851.
59. U.S. NRC (U.S. National Research Council). 1999. Arsenic in Drinking Water. Washington, DC:National Academy Press.
60. U.S. PHS (U.S. Public Health Service). 1989. Toxicological Profile for Arsenic. Washington, DC:U.S. Public Health Service.
61. Venkataraman M, Westerman MP. 1986. Susceptibility of human T cells, T-cell subsets, and B cells to cryopreservation. Cryobiology 23:199-208.
62. Verma S, Li SH, Badiwala MV, Weisel RD, Fedak PW, Li RK, et al. 2002. Endothelin antagonism and interleukin-6 inhibition attenuate the proatherogenic effects of C-reactive protein. Circulation 105:1890-1896.
63. Wang, CH, Jeng JS, Yip PK, Chen CL, Hsu LI, Hsueh YM, et al. 2002. Biological gradient between long-term arsenic exposure and carotid atherosclerosis. Circulation 105:1804-1809.
64. Wittwer CT, Herrmann MG, Moss AA, Rasmussen RP. 1997. Continuous fluorescence monitoring of rapid cycle DNA amplification. Biotechniques 22:130-131, 134-138.
65. Wolpe SD, Sherry B, Juers D, Davatelis G, Yurt RW, Cerami A. 1989. Identification and characterization of macrophage inflammatory protein 2. Proc Natl Aced Sci USA 86:612-616.
66. Wu MM, Chiou HY, Wang TW, Hsueh YM, Wang IH, Chen CJ, et al. 2001. Association of blood arsenic levels with increased reactive oxidants and decreased antioxidant capacity in a human population of northeastern Taiwan. Environ Health Perspect 109:1011-1017.
67. Yeh S, How SW. 1963. A pathological study on the blackfoot disease in Taiwan. Rep Inst Pathol Natl Taiwan Univ 14:25-73.
68. Yih LH, Peck K, Lee TC. 2002. Changes in gene expression profiles of human fibroblasts in response to sodium arsenite treatment. Carcinogenesis 23:867-876.
69. Zhao CQ, Young MR, Diwan BA, Coogan TP, Waalkes MP. 1997. Association of arsenic-induced malignant transformation with DNA hypomothylation and aberrant gene expression. Proc Natl Acad Sci USA 94:10907-10912.